Medications

FDA panel narrowly sides against experimental ALS drug

Federal health advisers on Wednesday narrowly ruled against an experimental drug for the debilitating illness known as Lou Gehrig's disease, a potential setback for patient groups who have lobbied for the medication's approval.

Medications

FDA reviewers give thumbs down to new ALS drug

Despite months of intense lobbying by patient advocates, federal health officials on Monday posted a largely negative review of an experimental drug for amyotrophic lateral sclerosis (ALS).

Medications

FDA skeptical of benefits from experimental ALS drug

Federal health regulators issued a negative review Monday of a closely watched experimental drug for the debilitating illness known as Lou Gehrig's disease, after months of lobbying by patient advocates urging approval.

page 7 from 24